Outpatient treatment of emergency department patients diagnosed with venous thromboembolism

References

• Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013 Sep;126(9):832 e13–21.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999 Mar 8;159(5):445–453.
   PubMedGoogle Scholar
• Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2363–2371.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Wang Y, Jimenez D, et al. Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999-2015. Jama. 2019 Aug 13;322(6):574–576.
   PubMed Web of Science ®Google Scholar
• Keller K, Hobohm L, Ebner M, et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J. 2020 Jan 21;41(4):522–529.
   PubMed Web of Science ®Google Scholar
• Lehnert P, Lange T, Moller CH, et al. Acute pulmonary embolism in a National Danish Cohort: increasing incidence and decreasing mortality. Thromb Haemost. 2018 Mar;118(3):539–546.
   PubMed Web of Science ®Google Scholar
• Weeda ER, Butt S. Systematic review of real-world studies evaluating characteristics associated with or programs designed to facilitate outpatient management of deep vein thrombosis. Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):301S–313S.
   PubMedGoogle Scholar
• Singer AJ, Thode HC Jr., Peacock W. Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. Clin Exp Emerg Med. 2016 Sep;3(3):126–131.
   PubMed Web of Science ®Google Scholar
• Fang MC, Fan D, Sung SH, et al. Outcomes in adults with acute pulmonary embolism who are discharged from emergency departments: the cardiovascular research network venous thromboembolism study. JAMA Intern Med. 2015 Jun;175(6):1060–1062.
   PubMed Web of Science ®Google Scholar
• Vinson DR, Ballard DW, Huang J, et al. Outpatient management of emergency department patients with acute pulmonary embolism: variation, patient characteristics, and outcomes. Ann Emerg Med. 2018 Jul;72(1):62–72 e3.
   PubMed Web of Science ®Google Scholar
• Westafer LM, Shieh MS, Pekow PS, et al. Outpatient management of patients following diagnosis of acute pulmonary embolism. Acad Emerg Med. 2021;28(3):336-345. DOI: 10.1111/acem.14181.
   Google Scholar
• Jimenez D, Bikdeli B, Barrios D, et al. Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. Int J Cardiol. 2018 Oct 15;269:327–333.
   PubMed Web of Science ®Google Scholar
• Lin BW, Schreiber DH, Liu G, et al. Therapy and outcomes in massive pulmonary embolism from the emergency medicine pulmonary embolism in the real world registry. Am J Emerg Med. 2012 Nov;30(9):1774–1781.
   PubMed Web of Science ®Google Scholar
• Elias A, Mallett S, Daoud-Elias M, et al. Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis. BMJ Open. 2016 Apr 29;6(4):e010324.
   PubMed Web of Science ®Google Scholar
• Donzé J, Le GG, Mj F, et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost. 2008 Nov;100(5):943–948.
   PubMed Web of Science ®Google Scholar
• Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011 Jul 2;378(9785):41–48.
   PubMed Web of Science ®Google Scholar
• Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010 Aug 9;170(15):1383–1389.
   PubMedGoogle Scholar
• Vali Y, Ladwa R, Bailie E, et al.Investigating and managing suspected pulmonary embolism in an outpatient setting: the Leicester experience. Thorax. 2015 Mar;70(3):291–293.
   PubMed Web of Science ®Google Scholar
• Roy PM, Corsi DJ, Carrier M, et al. Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism. J Thromb Haemost. 2017 Apr;15(4):685–694.
   PubMed Web of Science ®Google Scholar
• Piazza G. Listen to your heart (but don’t look at theirs): risk assessment for home treatment of pulmonary embolism. Am J Respir Crit Care Med. 2020 Jul 1;202(1):20–21.
   PubMed Web of Science ®Google Scholar
• Kline JA, Kahler ZP, Beam DM. Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance. Patient Prefer Adherence. 2016;10:561–569.
   PubMed Web of Science ®Google Scholar
• Kline J, Adler D, Alanis N, et al. Study protocol for a multicentre implementation trial of monotherapy anticoagulation to expedite home treatment of patients diagnosed with venous thromboembolism in the emergency department. BMJ Open. 2020 Oct 1;10(10):e038078.
   PubMed Web of Science ®Google Scholar
• Kline J, Adler DH, Bledsoe JR, et al. Monotherapy anticoagulation to expedite home treatment of patients diagnosed with venous thromboembolism in the emergency department: a pragmatic effectiveness trial. Circ Cardiovasc Qual Outcomes. 2021 In press
   PubMed Web of Science ®Google Scholar
• Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005 Oct 15;172(8):1041–1046.
   PubMed Web of Science ®Google Scholar
• Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010 Aug 9;170(15):1383–1389.
   PubMedGoogle Scholar
• Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia study. J Thromb Haemost. 2011 Aug;9(8):1500–1507.
   PubMed Web of Science ®Google Scholar
• Zhou XY, Ben SQ, Chen HL, et al. The prognostic value of pulmonary embolism severity index in acute pulmonary embolism: a meta-analysis. Respir Res. 2012 Dec;4(13):111.
   Google Scholar
• Yamashita Y, Morimoto T, Amano H, et al. Validation of simplified PESI score for identification of low-risk patients with pulmonary embolism: from the COMMAND VTE Registry. Eur Heart J Acute Cardiovasc Care. 2020 Jun;9(4):262–270.
   PubMed Web of Science ®Google Scholar
• Wells P, Peacock WF, Fermann GJ, et al. The value of sPESI for risk stratification in patients with pulmonary embolism. J Thromb Thrombolysis. 2019 Jul;48(1):149–157.
   PubMed Web of Science ®Google Scholar
• Donze J, Le Gal G, Fine MJ, et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost. 2008 Nov;100(5):943–948.
   PubMed Web of Science ®Google Scholar
• Den Exter PL, Zondag W, Klok FA, et al. Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without n-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism. A Randomized Clinical Trial. Am J Respir Crit Care Med. 2016 Oct 15;194(8):998–1006.
   PubMed Web of Science ®Google Scholar
• Beam DM, Kahler ZP, Kline JA. Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. emergency departments: a one-year preplanned analysis. Academic emergency medicine. Acad Emerg Med. 2015 Jul;22(7):788–795.
   Google Scholar
• Righini M, Roy PM, Meyer G, et al. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost. 2011 Oct;9(10):2115–2117.
   PubMed Web of Science ®Google Scholar
• Sam A, Sánchez D, Gómez V, et al. The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism. Eur Respir J. 2011 Apr;37(4):762–766.
   PubMed Web of Science ®Google Scholar
• Quezada CA, Bikdeli B, Villen T, et al. Accuracy and interobserver reliability of the simplified pulmonary embolism severity index versus the Hestia criteria for patients with pulmonary embolism. Acad Emerg Med. 2019 Apr;26(4):394–401.
   PubMed Web of Science ®Google Scholar
• Barco S, Mahmoudpour SH, Planquette B, et al. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2019 Mar 14;40(11):902–910.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543–603.
   PubMed Web of Science ®Google Scholar
• Probst MA, Kanzaria HK, Schoenfeld EM, et al. Shared decisionmaking in the emergency department: a guiding framework for clinicians. Ann Emerg Med. 2017 Nov;70(5):688–695.
   PubMed Web of Science ®Google Scholar
• Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996 Mar 14;334(11):682–687.
   PubMed Web of Science ®Google Scholar
• Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996 Mar 14;334(11):677–681.
   PubMed Web of Science ®Google Scholar
• Nathan AS, Geng Z, Dayoub EJ, et al. Racial, ethnic, and socioeconomic inequities in the prescription of direct oral anticoagulants in patients with venous thromboembolism in the United States. Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005600.
   PubMed Web of Science ®Google Scholar
• Lutsey PL, Walker RF, MacLehose RF, et al. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Res Pract Thromb Haemost. 2019 Oct;3(4):668–673.
   PubMed Web of Science ®Google Scholar
• Frank Peacock W, Coleman CI, Diercks DB, et al. Emergency department discharge of pulmonary embolus patients. Academic emergency medicine. Acad Emerg Med. 2018 Sep;25(9):995–1003.
   Google Scholar
• Kahler ZP, Beam DM, Kline JA. Cost of treating venous thromboembolism with heparin and warfarin versus home treatment with rivaroxaban. Acad Emerg Med. 2015 Jul;22(7):796–802.
   PubMed Web of Science ®Google Scholar
• Fanikos J, Rao A, Seger AC, et al. Hospital costs of acute pulmonary embolism. Am J Med. 2013 Feb;126(2):127–132.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692–694.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med. 2012 Apr 5;366(14):1287–1297.
   PubMed Web of Science ®Google Scholar
• Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010 Dec 23;363(26):2499–2510.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342–2352.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764–772.
   PubMed Web of Science ®Google Scholar
• Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New Engl J Med. 2013 Oct 10;369(15):1406–1415.
   PubMed Web of Science ®Google Scholar
• Stampfuss J, Kubitza D, Becka M, et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013 Jul;51(7):549–561.
   PubMed Web of Science ®Google Scholar
• Scheres L, Brekelmans M, Ageno W, et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. BJOG. 2018 Nov;125(12):1581–1589.
   PubMed Web of Science ®Google Scholar
• Ferreira M, Barsam S, Patel JP, et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol. 2016 Apr;173(2):314–315.
   PubMed Web of Science ®Google Scholar
• De Crem N, Peerlinck K, Vanassche T, et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015 Oct;136(4):749–753.
   PubMed Web of Science ®Google Scholar
• Brekelmans MP, Scheres LJ, Bleker SM, et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thromb Haemost. 2017 Apr 3;117(4):809–815.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Michalski F, Tittl L, et al. Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy. Thromb Haemost. 2016 Jun 2;115(6):1234–1236.
   PubMed Web of Science ®Google Scholar
• Hogg K, Panag A, Worster A, et al. Direct oral anticoagulants: a practical guide for the emergency physician. Eur J Emerg Med. 2016 Oct;23(5):330–336.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008 Aug 26;179(5):417–426.
   PubMed Web of Science ®Google Scholar
• Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012 Jun;10(6):1019–1025.
   PubMed Web of Science ®Google Scholar
• Tosetto A, Testa S, Martinelli I, et al. External validation of the DASH prediction rule: a retrospective cohort study. J Thromb Haemost. 2017 Oct;15(10):1963–1970.
   PubMed Web of Science ®Google Scholar
• Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010 Apr 13;121(14):1630–1636.
   PubMed Web of Science ®Google Scholar
• Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc. 2014 Jan 2;3(1):e000467.
   PubMed Web of Science ®Google Scholar
• Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016 May 6;6(5):e011190.
   PubMed Web of Science ®Google Scholar
• Klok FA, Hosel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016 Nov;48(5):1369–1376.
   PubMed Web of Science ®Google Scholar
• Klok FA, Barco S, Konstantinides SV. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thromb Haemost. 2017 Jun 2;117(6):1164–1170.
   PubMed Web of Science ®Google Scholar
• Kline JA, Jimenez D, Courtney DM, et al. Comparison of four bleeding risk scores to identify rivaroxaban-treated patients with venous thromboembolism at low risk for major bleeding. Acad Emerg Med. 2016 Feb;23(2):144–150.
   PubMed Web of Science ®Google Scholar
• Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2018 Jan;9(1):CD003076.
   Google Scholar
• Khatib R, Ross S, Kennedy SA, et al. Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. Blood Adv. 2020 Feb 11;4(3):500–513.
   PubMed Web of Science ®Google Scholar
• Yoo HH, Nunes-Nogueira VS, Fortes Villas Boas PJ, et al. Outpatient versus inpatient treatment for acute pulmonary embolism. Cochrane Database Syst Rev. 2019 Mar;6(3):CD010019.
   Google Scholar
• Maughan BC, Frueh L, McDonagh MS, et al. Outpatient treatment of low-risk pulmonary embolism in the era of direct oral anticoagulants: a systematic review. Acad Emerg Med. 2020 Aug 11;28(2):226–239.
   PubMed Web of Science ®Google Scholar
• Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015 Aug;12(8):464–474.
   PubMed Web of Science ®Google Scholar
• Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006 Mar;4(3):529–535.
   PubMed Web of Science ®Google Scholar
• Otten HM, Mathijssen J, Ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004 Jan 26;164(2):190–194.
   PubMed Web of Science ®Google Scholar
• Den Exter PL, Gomez V, Jimenez D, et al. A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. Chest. 2013 Jan;143(1):138–145.
   PubMed Web of Science ®Google Scholar
• Kline JA, Roy PM, Than MP, et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE-C tool. Thromb Res. 2012 May;129(5):e194–9.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902–4907.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019 Feb 21;380(8):720–728.
   PubMed Web of Science ®Google Scholar
• Van Der Hulle T, Den Exter PL, Kooiman J, et al. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014 Jul;12(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• Prins MH, Lensing AW, Brighton TA, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014 Oct;1(1):e37–46.
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Germini F, Agnelli G, et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015 Feb;147(2):475–483.
   PubMed Web of Science ®Google Scholar
• Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014 Dec;134(6):1214–1219.
   PubMed Web of Science ®Google Scholar
• Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018 Jun;19(6):CD006650.
   Google Scholar
• Martinez-Zapata MJ, Mathioudakis AG, Mousa SA, et al. Tinzaparin for long-term treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2018 Mar;24(2):226–234.
   PubMed Web of Science ®Google Scholar
• Posch F, Konigsbrugge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015 Sep;136(3):582–589.
   PubMed Web of Science ®Google Scholar
• Raskob GE, Van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615–624.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017–2023.
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020 Feb 10;38(5):496–520.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019 Feb 21;380(8):711–719.
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018 Dec 14;39(47):4208–4218.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019 Sep;54(3). 10.1183/13993003.01647-2019.
   PubMed Web of Science ®Google Scholar
• Howard L, Barden S, Condliffe R, et al. British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax. 2018 Jul;73(Suppl 2):ii1–ii29.
   PubMedGoogle Scholar
• American College of Emergency Physicians Clinical Policies Subcommittee on Thromboembolic Disease, Wolf SJ, Hahn SA, Nentwich LM, et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected acute venous thromboembolic disease. Ann Emerg Med. 2018 May;71(5):e59–e109.
   PubMedGoogle Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e419S–e496S.
   PubMed Web of Science ®Google Scholar
• Mastroiacovo D, Dentali F, Di Micco P, et al. Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. Eur Respir J. 2019;53(2):Feb.
   Web of Science ®Google Scholar
• Schulman S, Singer D, Ageno W, et al. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost. 2017 Jun 28;117(7):1317–1325.
   PubMed Web of Science ®Google Scholar
• Hendriks SV, Klok FA, Stenger WJE, et al. Effectiveness and safety of apixaban for treatment of venous thromboembolism in daily practice. TH Open. 2020 4;Apr(2):e119–e126.
   Google Scholar
• Weycker D, Li X, Wygant GD, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in. Thromb Haemost. 2018 Nov;118(11):1951–1961.
   Google Scholar
• DeCamillo D, Ellsworth S, Kaatz S, et al. Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series. J Thromb Thrombolysis. 2020 Nov;50(4):844–848.
   PubMed Web of Science ®Google Scholar
• Vinson DR, Mark DG, Chettipally UK, et al. Increasing safe outpatient management of emergency department patients with pulmonary embolism: a controlled pragmatic trial. Ann Intern Med.2018 Dec 18;169(12):855–865.
   PubMed Web of Science ®Google Scholar
• Ageno W, Mantovani LG, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016 Jan;3(1):e12–21.
   PubMed Web of Science ®Google Scholar
• Bledsoe JR, Woller SC, Stevens SM, et al. Management of low-risk pulmonary embolism patients without hospitalization: the low-risk pulmonary embolism prospective management study. Chest. 2018 Aug;154(2):249–256.
   PubMed Web of Science ®Google Scholar
• Barco S, Schmidtmann I, Ageno W, et al. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J. 2020 Jan 21;41(4):509–518.
   PubMed Web of Science ®Google Scholar
• Evans A, Davies M, Osborne V, et al. Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study. BMJ Open. 2020 Nov 3;10(11):e038102.
   PubMed Web of Science ®Google Scholar